Advances in Research on IL-37 in Inflammatory Bowel Disease
10.3969/j.issn.1008-7125.2020.05.012
- VernacularTitle: IL-37在炎症性肠病中的研究进展
- Author:
Shangjian LUO
1
Author Information
1. Department of Gastroenterology, School of Medicine, Shanghai Jiao Tong University
- Publication Type:Journal Article
- Keywords:
Immune Response;
Inflammatory Bowel Disease;
Interleukin-37
- From:
Chinese Journal of Gastroenterology
2020;25(5):309-313
- CountryChina
- Language:Chinese
-
Abstract:
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a chronic and nonspecific intestinal inflammatory disease. Immune response disorder is one of the important links in the pathogenesis of IBD. Cytokines participate in the development and remission of IBD by modulating immune response. Interleukin-37 (IL-37), an anti-inflammatory cytokine, can inhibit the excessive immune response through extracellular and intracellular pathways. Several studies have shown that IL-37 can limit intestinal inflammation damage and promote inflammation remission, and play an important protective role in IBD. This article reviewed the research progress on IL-37 in IBD.
